doi:10.1097/MCO.0000000000000883 68
For example, HCPs should discuss the importance of balanced nutritional intake with all patients prescribed GLP-1 RAs, alongside monitoring signs of malnutrition, micronutrient status, and changes in body composition
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review
Adding glucagon receptor activation to GIP and GLP-1 was theoretically promising but practically uncertain
The trial included around 800 people who already had advanced fatty liver disease including signs of liver damage and inflammation
The integrated workflow encompassing data extraction, preprocessing, and analytical procedures is illustrated in Fig